Eli Lilly and Company has entered a definitive agreement to acquire Ventyx Biosciences, as part of an effort to develop more oral therapies for inflammatory-mediated diseases.
The all-cash transaction has an aggregate equity value of approximately $1.2 billion. Lilly will be purchasing outstanding shares for $14.00 per share of common stock, not subject to any financing condition. The deal is expected to close in the first half of 2026.
Ventyx is a clinical-stage biopharmaceutical company that develops small molecule therapeutics to treat chronic inflammation in various disease states. Its main aim is to provide treatments that have higher efficacy and safety than current drugs on the market. The company’s therapeutics include NLRP3 inhibitors, which treat inflammation in cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders.